NEW YORK (GenomeWeb News) – The US Food and Drug Administration said today that it has cleared for marketing a microarray-based test from Pathwork Diagnostics that determines what type of cancer cells are present in a malignant tumor.
 
The Pathwork Tissue of Origin test is based on Pathwork’s PathChip gene-expression array, which runs on Affy’s GCS3000Dx diagnostic platform. The test considers 15 common malignant tumor types, including bladder, breast, and colorectal tumors.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.